Table 1 Clinical characteristics of the study cohort (n = 9)
From: Longitudinal analysis of individual cfDNA methylome patterns in metastatic prostate cancer
Mean agea, years (range) | 64.2 (51–74) |
Gleason score at diagnosisb, n (%) | |
7 (3 + 4) | 5 (55.6) |
9 | 4 (44.4) |
Metastatic sites, n (%) | |
Bone | 9 (100) |
Lymph node | 2 (22.2) |
Evidence of castration resistance at recruitment (cohort)c, n (%) | |
No (mPCa; cohort 1) | 5 (55.6) |
Yes (mCRPC; cohort 2) | 4 (44.4) |
Number of timepointsd, n (%) | |
4 | 2 (22.2) |
5 | 2 (22.2) |
6 | 5 (55.6) |
Mean cfDNA concentratione, ng/ul (range) | 5.08 (0.61–38) |
Mean PSA levelse, ng/ml (range) | 35.3 (0.1–352.1) |
Therapies administeredf, n (%) | |
LHRH agonists/antagonists | 8 (88.9) |
Taxanes | 9 (100) |
AR-inhibitors | 8 (88.9) |
Radioisotopes | 3 (33.3) |
Mean follow-up timeg, months (range) | 19.1 (13–21) |